Work pursuing #GPC3 #radiotheranostics using PDX models could validate these findings and offer a much needed therapeutic option for this rare, difficult to treat cancer.

For this story, we asked whether we could explore expression in patient samples (PDXs, PDOs, cell lines, IHC of tumors) more sytematically and whether we could use #GPC3 as a #radiopharmaceutical target for #NEPC.

Turns out that GPC3 is highly enriched in patients with AR-/NE+ prostate cancers!

Oncofetal protein glypican‐3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer Neuroendocrine (NE) cells comprise ~1% of epithelial cells in benign prostate and prostatic adenocarcinoma (PCa). However, they become enriched in hormonally treated and castration-resistant PCa (CRP...

So, it's perhaps no surprise that when we came across the work by out of Duke showing that #GPC3 was also expressed in neuroendocrine prostate cancer #nepc, it piqued our interest!

doi.org/10.1002/path...

Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3–Expressing Liver Cancer by Immuno-PET Primary liver cancer is the third leading cause of cancer-related deaths, and its incidence and mortality are increasing worldwide. Hepatocellular carcinoma (HCC) accounts for 80% of primary liver can...

As some of you might know, our group has long been interested in using #GPC3 as an #HCC-selective target to develop #radiopharmaceuticals.

Example: jnm.snmjournals.org/content/64/7...